09/24/14 - 10:30 AM EDT
TAF is an improved version of Gilead's stalwart but patent challenged HIV drug Viread.READ FULL POST
09/24/14 - 08:14 AM EDT
Baxter has a hunger for cancer drugs with hair.READ FULL POST
09/22/14 - 07:48 PM EDT
Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.READ FULL POST
09/22/14 - 08:59 AM EDT
The buyers of Northwest's debt want the stock price to decline before Feb. 15, 2015, because a lower stock price also will drop the conversion price of the notes.READ FULL POST
09/19/14 - 12:05 PM EDT
Activist investor Alex Denner is gaining an ally on Ariad's Board.READ FULL POST
09/16/14 - 01:04 PM EDT
On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.READ FULL POST
09/15/14 - 10:19 AM EDT
Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow highREAD FULL POST
09/12/14 - 09:43 AM EDT
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.READ FULL POST
09/11/14 - 01:23 PM EDT
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.READ FULL POST
09/10/14 - 03:37 PM EDT
Language in the new Xtandi label should help Medivation and Astellas widen their market share lead over Johnson & Johnson's competing prostate cancer drug Zytiga.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.